Fresenius Kabi’s 1st-to-marketplace generic version of Foscavir® (foscarnet sodium injection) is now offered.

Foscarnet sodium injection is indicated to deal with cytomegalovirus (CMV) retinitis in individuals with AIDS. Mixture treatment of Foscarnet Sodium Injection and ganciclovir is indicated for sufferers who have relapsed after monotherapy with either drug. It is also indicated for the treatment method of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) bacterial infections in immunocompromised sufferers.

The basic safety and efficacy of Foscarnet Sodium Injection have not been proven for cure of other CMV bacterial infections (ie, pneumonitis, gastroenteritis), other HSV bacterial infections (ie, retinitis, encephalitis), congenital or neonatal CMV or HSV condition, or in nonimmunocompromised people.

Fresenius Kabi’s Foscarnet Sodium Injection is provided in 250mL bottles made up of 6000mg of foscarnet sodium (24mg/mL).

“We’re delighted to offer this initial-to-market generic for Foscavir in the United States, an essential cure for immune-compromised patients,” said John Ducker, president and CEO of Fresenius Kabi United states of america.

Reference

Fresenius Kabi Introduces To start with-Ever Generic for Foscavir® (Foscarnet Sodium) Injection. [press release]. Lake Zurich, IL: Fresenius Kabi March 15, 2021.